Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery

NCT ID: NCT02177955

Last Updated: 2014-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned third molars.

Study design: A prospective, randomized, double-blind, clinical trial was carried out involving 120 patients divided in three groups: Group 1 (diazepam and placebo), Group 2 (midazolam and placebo) and Group 3 (diazepam and midazolam). Each subject underwent two surgeries on separate occasions under local anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design A double-blind, randomized, crossover, clinical trial with a split-mouth design was carried out. This study received approval from the Human Research Ethics Committee of the institution at which it was carried out (process number: 001.0.097.000-08) and was conducted in compliance with the Consolidated Standards of Reporting Trials (CONSORT) statement. All patients signed a statement of informed consent agreeing to participate in the study.

Sample size and pilot study The sample size was estimated using the a computational program. Thirty patients were submitted to third molar surgeries in a pilot study to determine the sample size. This step was necessary due to the lack of similar studies in the literature. Calculations were performed with specific programs taking into consideration the variables, a 95% confidence interval, 80% test power and 5% error. At the end of the study, 120 patients were analyzed (40 in each group), totaling 240 surgeries.

Sample selection One hundred twenty eight individuals between 18 and 40 years of age were selected for participation in the present study and submission to maxillary and mandibular third molar extractions bilaterally at the Department of Oral-Maxillofacial Surgery. Each patient was to be submitted to two surgeries. The third molars (maxillary or mandibular) needed to have the same degree of impaction on both sides.

Three groups were formed: Group A received diazepam and placebo, Group B received midazolam and placebo and Group C received midazolam and diazepam. For the purposes of randomization and blinding of the surgeon and researcher in charge of analyzing the results, the groups were renominated Groups 1, 2 and 3. The randomization procedure was carried out by a researcher who was not directly involved in the surgeries or evaluations. Sequentially numbered, sealed, opaque envelopes were used, each containing a combination of substances and the side to be submitted to the first surgery. For each patient, the researcher opened an envelope, informed the main investigator and surgeon of the side to be operated, and administered the substance to the patient. The second surgery was performed on the contralateral side with the administration of the second substance. Blinding was performed to avoid awareness regarding what substance was administered in each surgery. For such, the pills were fabricated with the same outer color and a standardized size at the Pernambuco Pharmaceutical Laboratory (Brazil) and were packaged in recipients with the same color. The recipients were denominated 1, 2 and 3.

Surgical procedures and medications As the patients were classified as healthy, no prophylactic use of antibiotics was performed prior to surgery for the prevention of bacterial endocarditis, as recommended by the American Heart Association. All patients rinsed their mouths with 0.12% chlorhexidine for one minute prior to surgery to reduce the bacterial population in the oral cavity. Moreover, all patients were instructed to take two 4-mg pills of dexamethasone one hour prior to surgery. The use of a corticosteroid in the preoperative period minimizes the occurrence of postoperative swelling and reduces the risk of trismus.13 The substances (diazepam, midazolam and placebo) were administered orally 45 minutes prior to the surgical procedure. As the substances were masked, neither the surgeon nor the patient was aware of what substance was given (double-blind study).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Third Molar Anty-anxiety drugs hemodynamic Benzodiazepines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

midazolan

7.5 mg midazolan 45 minutes before the surgery

Group Type PLACEBO_COMPARATOR

7.5 mg Midazolam

Intervention Type DRUG

7.5 mg midazolam 45 minutes before surgery

diazepam

10 mg diazepam 45 minutes before the surgery

Group Type PLACEBO_COMPARATOR

10 mg diazepam

Intervention Type DRUG

10 mg midazolam 45 minutes before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

7.5 mg Midazolam

7.5 mg midazolam 45 minutes before surgery

Intervention Type DRUG

10 mg diazepam

10 mg midazolam 45 minutes before surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:

* The inclusion criteria were classification in Group 1 of the American Society of Anesthesiology (normal healthy patient with no adverse systemic condition or continuous use of medication) and no self-reported reactions or allergies to the drugs employed in the study

Exclusion Criteria:

* The exclusion criteria were refusal to participate after reading the statement of informed consent, self-reported allergy to the drugs employed and failure to return for the second surgery on the contralateral side
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pernambuco

OTHER

Sponsor Role collaborator

Jimmy Barbalho

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jimmy Barbalho

DDs

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hécio H De Morais, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pernambuco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

School of Dentistry of Pernambuco

Recife, Pernambuco, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

001.0.097.000-08

Identifier Type: OTHER

Identifier Source: secondary_id

001.0.097.000-08

Identifier Type: -

Identifier Source: org_study_id